Shots: The approval is based on the study assessing Ruzurgi vs PBO in 32 adult patients while patients taking Ruzurgi for at least three months prior to entering the study The study measured effectiveness of a patient to rise from a chair, walk three meters & return to the chair for three consecutive laps without […]Read More
Tags : amifampridine
Regulatory
Catalyst’s Firdapse (amifampridine) Receives FDA’s Approval for Lambert-Eaton Myasthenic Syndrome
Shots: The approval is based on two clinical trial results assessing Firdapse vs PBO in 64 patients with Lambert-Eaton Myasthenic Syndrome The study measured Quantitative Myasthenia Gravis score (assessing muscle weakness) and demonstrated overall impression having effective results vs PBO Firdapse (amifampridine) is an EU approved drug in Dec 2009, indicated for symptomatic treatment of […]Read More
Latest Posts
